Key result
Gemcitabine, docetaxel, and bevacizumab yielded a 6-month progression-free survival of 65% (95% CI 51-85%) in soft tissue sarcoma, failing to meet the primary endpoint due to patient withdrawals.
Why the study?
Does the addition of bevacizumab to gemcitabine and docetaxel improve progression-free survival in patients with soft tissue sarcoma?
Does the addition of bevacizumab to gemcitabine and docetaxel improve progression-free survival in patients with soft tissue sarcoma?
The addition of bevacizumab to gemcitabine and docetaxel in soft tissue sarcoma did not meet its primary 6-month PFS endpoint due to censoring, but showed promising 3-month PFS and response rates.
No takes yet. Share an insight, caveat, or question.
Bevacizumab addition should not yet alter gemcitabine-docetaxel use in soft tissue sarcoma; leaves open potential PFS benefit pending randomized data.
Dickson et al. (2015) studied recurrent/metastatic soft tissue sarcoma (n=44). Gemcitabine, docetaxel, and bevacizumab was evaluated on progression-free survival (PFS) at 6 months (95% CI 51-85). Gemcitabine, docetaxel, and bevacizumab yielded a 6-month progression-free survival of 65% (95% CI 51-85%) in soft tissue sarcoma, failing to meet the primary endpoint due to patient withdrawals.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: